Study of How Genetic Differences Affect the Way Women Process Combined Oral Contraceptive Pills Containing Desogestrel and Ethinyl Estradiol

What this Trial Is About

This research aims to understand how genetic differences affect the way individual bodies process hormones in combined oral contraceptive pills containing desogestrel and ethinyl estradiol. The study focuses on whether a specific genetic variant, CYP3A7*1C, influences hormone metabolism and breakthrough ovulation rates, and seeks to identify new genetic factors that impact hormone levels and effects in pill users. Participants will take a combined oral contraceptive pill with a fixed dose of desogestrel and ethinyl estradiol for at least one 21-day cycle and up to 13 cycles one year. During the study, blood samples will be taken to measure hormone levels and biomarkers, and participants will complete questionnaires about possible side effects. An optional transvaginal ultrasound may be performed to check ovarian follicles. Throughout the study, hormone concentrations such as etonogestrel and ethinyl estradiol will be measured at set time points, primarily on Day 22 of the first cycle. Additional assessments include measurements of other hormones and mood questionnaires at various cycles. Researchers will monitor side effects and hormone effects, with the total participation lasting up to one year under medical supervision.

Oral Contraceptive Pill (OCP) Pharmacogenomics